QR-kod

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Up to 20% of all non-small cell lung cancer patients harbor tumor specific driver mutations that are effectively treated with tyrosine kinase inhibitors. However, for the rare EGFR deletion-insertion mutation of exon 18, there is very little evidence regarding the effectiveness of tyrosine kinase in...

Full beskrivning

Sparad:
Huvudupphov: Michael Cekay, Philipp F. Arndt, Rio Dumitrascu, Rajkumar Savai, Andreas Braeuninger, Stefan Gattenloehner, Dagmar Steiner, Fritz Roller, Khodr Tello, Katja Hattar, Werner Seeger, Ulf Sibelius, Friedrich Grimminger, Bastian Eul
Materialtyp: Artigo
Språk:Inglês
Utgiven: Frontiers Media S.A. 2023-08-01
Serie:Frontiers in Oncology
Ämnen:
non-small cell lung cancer
EGFR mutation
tyrosine kinase inhibitors (TKIs)
Osimertinib
EGFR Exon 18 insertion
Länkar:https://www.frontiersin.org/articles/10.3389/fonc.2023.1182391/full
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk